UNIVERSITATSSPITAL BASEL

Their core work

University Hospital Basel is a major Swiss teaching hospital that contributes specialized clinical and translational research expertise to European research consortia. Their strengths span neuroscience (particularly brain simulation and neuroinformatics through the Human Brain Project), cancer biology (breast cancer metastasis, leukemia stem cells, tumor mechanics), and regenerative medicine (cartilage, bone, and disc regeneration). They consistently serve as a third-party contributor, providing clinical validation, patient-derived models, and disease-specific expertise that large EU projects need to bridge the gap between laboratory science and patient outcomes.

What they specialise in

How they've shifted over time

In the early period (2015-2018), Basel's contributions were split between foundational neuroscience (Human Brain Project phases 1-2), cancer biomechanics (FORCE, measuring tumor interstitial fluid pressure via MR-elastography), and classical regenerative medicine (BIO-CHIP, ELASTISLET). From 2019 onward, the neuroscience work continued into HBP SGA3 with a clear shift toward the EBRAINS research infrastructure, while new projects leaned heavily into advanced therapeutics — CAR T cell engineering (TALE), RNA-based bone regeneration (cmRNAbone), and leukemia stem cell targeting (Hemstem). The trend shows a hospital moving from observational and modeling roles toward active therapeutic development, particularly in cell and gene therapy.

Basel is shifting from contributing disease models and clinical data toward developing therapeutic interventions, making them an increasingly relevant partner for translational medicine and advanced therapy projects.

How they like to work

Universitätsspital Basel operates exclusively as a third-party contributor — all 15 H2020 projects list them in this role, meaning they are brought in by consortium partners for specific clinical or research expertise rather than leading or formally participating. Despite this supporting role, they have connected with 302 unique partners across 26 countries, indicating they are widely trusted and frequently recruited. This pattern suggests a highly specialized contributor that adds clinical credibility and patient-proximate expertise without taking on project management overhead.

With 302 unique consortium partners across 26 countries, Basel maintains one of the broader networks you'd expect from a third-party contributor, reflecting the large-scale consortia they join (especially the Human Brain Project with hundreds of partners). Their reach is pan-European with strong connections into the EU research infrastructure ecosystem.

What sets them apart

What makes Universitätsspital Basel distinctive is the combination of a top-tier clinical hospital environment with deep computational neuroscience involvement — few hospitals bridge brain simulation infrastructure (HBP/EBRAINS) and hands-on cancer therapeutics development. Their consistent third-party role across 15 projects means they bring focused expertise without the administrative burden of formal partnership, making them a low-friction addition to consortia. For anyone building a project that needs clinical validation, patient-derived samples, or translational bridging between lab research and hospital application, Basel offers a proven track record in exactly that role.

Highlights from their portfolio

• HBP SGA3
  The culmination of the Human Brain Project — one of the EU's largest Flagship initiatives — where Basel contributed to building the EBRAINS research infrastructure for neuroscience.
• B2B
  Developed a first-of-its-kind 3D bioprinted device to model breast cancer metastasis to bone, combining biofabrication with high-throughput drug screening.
• Hemstem
  An ERC Synergy Grant (2021-2027) targeting leukemia by modulating hematopoietic stem cell competition — represents Basel's most recent and longest-running H2020 involvement.